About Yili Chuanning Biotechnology Company

The company was founded in December 2010 and is one of the largest domestic and global suppliers of antibiotic intermediates. As a strategic emerging industry relating to the national economy and people's livelihood, economic development and national security, the pharmaceutical (API) industry bears a major responsibility to guarantee the supply of pharmaceuticals and meet the diverse and multi-level health needs of the people, and is an important foundation for the national pharmaceutical industry and the construction of a healthy China. The company is mainly engaged in the development and industrialization of biological fermentation technology and synthetic biological products. The company's main products include erythromycin thiocyanate, cephalosporin intermediates (7-ACA, 7-ADCA, D-7ACA), penicillin intermediates (6-APA, penicillin G potassium salt), crude ursodeoxycholic acid, coenzyme Q10 mycelium, etc. Corporate honors: In 2019, the Xinjiang Uygur Autonomous Region Department of Industry and Information Technology approved the “Tianchi Doctor Program” project; approved as the “Xinjiang Uyghur Autonomous Region High-tech Enterprise” in 2020; the “National Environmental Protection Antibiotic Bacterial Residue Harmless Treatment and Resource Utilization Engineering Technology Center” established by the company passed the inspection; in 2021, it was approved by the Autonomous Region Human Resources and Social Security Department to establish the Autonomous Region Postdoctoral Research Workstation, etc. It won the honorary title of “National Model Worker”.